trending Market Intelligence /marketintelligence/en/news-insights/trending/ZiX4NVSuOKr7vw9nmbKdVQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Mérieux Equity invests in French pharmaceutical laboratory Addmedica

Key Credit Risk Factors When Assessing Banks In The Context Of COVID-19

Street Talk Episode 61 - Investors debate if U.S. banks have enough capital in post COVID world

You Down With PPP? Consider The Risks

Street Talk Episode 60 - You Down With PPP? Consider The Risks


Mérieux Equity invests in French pharmaceutical laboratory Addmedica

Mérieux Equity Partners SAS made an investment in French pharmaceutical laboratory Addmedica SAS through its Mérieux Participations 3 SLP fund.

The private equity firm became the reference shareholder of the company in partnership with founders François Anger and Bernard Dauvergne.

Addmedica develops and markets medicinal products and medical devices for rare diseases, including a benchmark treatment for inherited blood disorder sickle cell disease. The company will use the capital to expand its global footprint and product portfolio.

Duteil et Associés Law Firm and Advance Capital provided support to Mérieux Equity.